as of 02-27-2026 3:30pm EST
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.3B | IPO Year: | 2024 |
| Target Price: | $47.00 | AVG Volume (30 days): | 269.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.15 | EPS Growth: | 83.64 |
| 52 Week Low/High: | $6.43 - $42.27 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -13.64 | Index: | N/A |
| Free Cash Flow: | -67233000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Executive Officer
Avg Cost/Share
$26.11
Shares
10,916
Total Value
$285,070.92
Owned After
25,812
Chief Scientific Officer
Avg Cost/Share
$27.11
Shares
8,500
Total Value
$228,131.65
Owned After
395,575
Chief Scientific Officer
Avg Cost/Share
$30.05
Shares
6,567
Total Value
$197,337.69
Owned After
395,575
SEC Form 4
Chief Development Officer
Avg Cost/Share
$30.05
Shares
2,840
Total Value
$85,342.00
Owned After
296,991
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$29.97
Shares
10,916
Total Value
$323,508.33
Owned After
25,812
Chief Scientific Officer
Avg Cost/Share
$30.31
Shares
8,500
Total Value
$255,129.97
Owned After
395,575
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ceesay Abraham | RAPP | Chief Executive Officer | Jan 20, 2026 | Sell | $26.11 | 10,916 | $285,070.92 | 25,812 | |
| Bredt David | RAPP | Chief Scientific Officer | Jan 15, 2026 | Sell | $27.11 | 8,500 | $228,131.65 | 395,575 | |
| Bredt David | RAPP | Chief Scientific Officer | Dec 31, 2025 | Sell | $30.05 | 6,567 | $197,337.69 | 395,575 | |
| Yeleswaram Krishnaswamy | RAPP | Chief Development Officer | Dec 31, 2025 | Sell | $30.05 | 2,840 | $85,342.00 | 296,991 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Dec 17, 2025 | Sell | $29.97 | 10,916 | $323,508.33 | 25,812 | |
| Bredt David | RAPP | Chief Scientific Officer | Dec 15, 2025 | Sell | $30.31 | 8,500 | $255,129.97 | 395,575 |
See how RAPP stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "RAPP Rapport Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.